RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.33%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$740M
AUM Growth
+$740M
(-5.5%)
Cap. Flow
-$98.9M
Cap. Flow
% of AUM
-13.36%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$10.2M |
| 2 |
Gilead Sciences
GILD
|
$9.33M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$9.05M |
| 4 |
Cencora
COR
|
$8.66M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$6.55M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$30.6M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.4M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$10.1M |
| 4 |
AET
Aetna Inc
AET
|
$9.86M |
| 5 |
CVS Health
CVS
|
$9.76M |
Sector Composition
| 1 | Healthcare | 90.07% |
| 2 | Financials | 0.19% |
| 3 | Technology | 0.17% |
| 4 | Energy | 0.14% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LUMO
76
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.47M | 0.2% |
20,116
+9,005
| +81% | +$657K |
|
|
KERX
77
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $1.41M | 0.19% |
302,157
-97,843
| -24% | -$455K |
|
78
STAAR Surgical
STAA
$1.35B
| $1.18M | 0.16% |
76,256
-13,744
| -15% | -$213K |
|
|
NVRO
79
DELISTED
NEVRO CORP.
NVRO
| $1.05M | 0.14% |
15,145
-114,855
| -88% | -$7.93M |
|
|
TTPH
80
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.01M | 0.14% |
+8,045
| New | +$1.01M |
|
|
RARX
81
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $922K | 0.12% |
108,451
-11,246
| -9% | -$95.6K |
|
82
Halliburton
HAL
$18.4B
| $545K | 0.07% |
11,144
| – | – |
|
|
RGLS
83
DELISTED
Regulus Therapeutics
RGLS
| $513K | 0.07% |
4,107
-726
| -15% | -$90.7K |
|
84
JPMorgan Chase
JPM
$824B
| $483K | 0.07% |
4,518
-1,123
| -20% | -$120K |
|
85
Exxon Mobil
XOM
$477B
| $476K | 0.06% |
5,696
| – | – |
|
86
Wells Fargo
WFC
$258B
| $463K | 0.06% |
7,635
-1,018
| -12% | -$61.7K |
|
87
Janus Henderson
JHG
$6.86B
| $456K | 0.06% |
+11,906
| New | +$456K |
|
88
Adverum Biotechnologies
ADVM
$68.2M
| $445K | 0.06% |
12,701
-2,700
| -18% | -$94.6K |
|
89
Microsoft
MSFT
$3.76T
| $410K | 0.06% |
4,793
| – | – |
|
90
Pfizer
PFE
$141B
| $377K | 0.05% |
10,985
| – | – |
|
91
Ford
F
$46.2B
| $355K | 0.05% |
28,404
| – | – |
|
92
Qualcomm
QCOM
$170B
| $344K | 0.05% |
5,368
| – | – |
|
93
AB InBev
BUD
$116B
| $313K | 0.04% |
2,806
| – | – |
|
94
IBM
IBM
$227B
| $271K | 0.04% |
1,847
| – | – |
|
95
Gen Digital
GEN
$18.3B
| $263K | 0.04% |
9,359
| – | – |
|
|
96
CVS Health
CVS
$93B
| – | – |
-120,000
| Closed | -$9.76M |
|
97
Merck
MRK
$210B
| – | – |
-94,320
| Closed | -$5.76M |
|
98
Novo Nordisk
NVO
$252B
| – | – |
-160,000
| Closed | -$3.85M |
|
99
Sanofi
SNY
$122B
| – | – |
-130,000
| Closed | -$6.47M |
|
|
RAD
100
DELISTED
Rite Aid Corporation
RAD
| – | – |
-101,950
| Closed | -$4M |
|